The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Large Molecule Drugs CDMO Market Research Report 2025
Synopsis
The global Large Molecule Drugs CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Large Molecule Drugs CDMO in Biological Technology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Large Molecule Drugs CDMO include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Large Molecule Drugs CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Large Molecule Drugs CDMO.
Report Scope
The Large Molecule Drugs CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Large Molecule Drugs CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Large Molecule Drugs CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Large Molecule Drugs CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Large Molecule Drugs CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Large Molecule Drugs CDMO in Biological Technology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Large Molecule Drugs CDMO include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Large Molecule Drugs CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Large Molecule Drugs CDMO.
Report Scope
The Large Molecule Drugs CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Large Molecule Drugs CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Large Molecule Drugs CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Large Molecule Drugs CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Large Molecule Drugs CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cell Line Development
1.2.3 Large Molecule Drug Substance Development
1.3 Market by Application
1.3.1 Global Large Molecule Drugs CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biological Technology
1.3.3 Clinical
1.3.4 Pharmaceutical
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Large Molecule Drugs CDMO Market Perspective (2019-2030)
2.2 Large Molecule Drugs CDMO Growth Trends by Region
2.2.1 Global Large Molecule Drugs CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Large Molecule Drugs CDMO Historic Market Size by Region (2019-2024)
2.2.3 Large Molecule Drugs CDMO Forecasted Market Size by Region (2025-2030)
2.3 Large Molecule Drugs CDMO Market Dynamics
2.3.1 Large Molecule Drugs CDMO Industry Trends
2.3.2 Large Molecule Drugs CDMO Market Drivers
2.3.3 Large Molecule Drugs CDMO Market Challenges
2.3.4 Large Molecule Drugs CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Large Molecule Drugs CDMO Players by Revenue
3.1.1 Global Top Large Molecule Drugs CDMO Players by Revenue (2019-2024)
3.1.2 Global Large Molecule Drugs CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Large Molecule Drugs CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Large Molecule Drugs CDMO Revenue
3.4 Global Large Molecule Drugs CDMO Market Concentration Ratio
3.4.1 Global Large Molecule Drugs CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Large Molecule Drugs CDMO Revenue in 2023
3.5 Large Molecule Drugs CDMO Key Players Head office and Area Served
3.6 Key Players Large Molecule Drugs CDMO Product Solution and Service
3.7 Date of Enter into Large Molecule Drugs CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Large Molecule Drugs CDMO Breakdown Data by Type
4.1 Global Large Molecule Drugs CDMO Historic Market Size by Type (2019-2024)
4.2 Global Large Molecule Drugs CDMO Forecasted Market Size by Type (2025-2030)
5 Large Molecule Drugs CDMO Breakdown Data by Application
5.1 Global Large Molecule Drugs CDMO Historic Market Size by Application (2019-2024)
5.2 Global Large Molecule Drugs CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Large Molecule Drugs CDMO Market Size (2019-2030)
6.2 North America Large Molecule Drugs CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Large Molecule Drugs CDMO Market Size by Country (2019-2024)
6.4 North America Large Molecule Drugs CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Large Molecule Drugs CDMO Market Size (2019-2030)
7.2 Europe Large Molecule Drugs CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Large Molecule Drugs CDMO Market Size by Country (2019-2024)
7.4 Europe Large Molecule Drugs CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Large Molecule Drugs CDMO Market Size (2019-2030)
8.2 Asia-Pacific Large Molecule Drugs CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Large Molecule Drugs CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Large Molecule Drugs CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Large Molecule Drugs CDMO Market Size (2019-2030)
9.2 Latin America Large Molecule Drugs CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Large Molecule Drugs CDMO Market Size by Country (2019-2024)
9.4 Latin America Large Molecule Drugs CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Large Molecule Drugs CDMO Market Size (2019-2030)
10.2 Middle East & Africa Large Molecule Drugs CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Patheon
11.1.1 Patheon Company Detail
11.1.2 Patheon Business Overview
11.1.3 Patheon Large Molecule Drugs CDMO Introduction
11.1.4 Patheon Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.1.5 Patheon Recent Development
11.2 Eurofins Scientific
11.2.1 Eurofins Scientific Company Detail
11.2.2 Eurofins Scientific Business Overview
11.2.3 Eurofins Scientific Large Molecule Drugs CDMO Introduction
11.2.4 Eurofins Scientific Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.2.5 Eurofins Scientific Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Detail
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Large Molecule Drugs CDMO Introduction
11.3.4 Samsung Biologics Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.3.5 Samsung Biologics Recent Development
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Detail
11.4.2 Catalent, Inc. Business Overview
11.4.3 Catalent, Inc. Large Molecule Drugs CDMO Introduction
11.4.4 Catalent, Inc. Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.4.5 Catalent, Inc. Recent Development
11.5 Rentschler Biopharma SE
11.5.1 Rentschler Biopharma SE Company Detail
11.5.2 Rentschler Biopharma SE Business Overview
11.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Introduction
11.5.4 Rentschler Biopharma SE Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.5.5 Rentschler Biopharma SE Recent Development
11.6 AGC Biologics
11.6.1 AGC Biologics Company Detail
11.6.2 AGC Biologics Business Overview
11.6.3 AGC Biologics Large Molecule Drugs CDMO Introduction
11.6.4 AGC Biologics Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.6.5 AGC Biologics Recent Development
11.7 Recipharm AB
11.7.1 Recipharm AB Company Detail
11.7.2 Recipharm AB Business Overview
11.7.3 Recipharm AB Large Molecule Drugs CDMO Introduction
11.7.4 Recipharm AB Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.7.5 Recipharm AB Recent Development
11.8 Siegfried Holding AG
11.8.1 Siegfried Holding AG Company Detail
11.8.2 Siegfried Holding AG Business Overview
11.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Introduction
11.8.4 Siegfried Holding AG Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.8.5 Siegfried Holding AG Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Scorpius
11.10.1 Scorpius Company Detail
11.10.2 Scorpius Business Overview
11.10.3 Scorpius Large Molecule Drugs CDMO Introduction
11.10.4 Scorpius Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.10.5 Scorpius Recent Development
11.11 Ardena
11.11.1 Ardena Company Detail
11.11.2 Ardena Business Overview
11.11.3 Ardena Large Molecule Drugs CDMO Introduction
11.11.4 Ardena Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.11.5 Ardena Recent Development
11.12 Alcami
11.12.1 Alcami Company Detail
11.12.2 Alcami Business Overview
11.12.3 Alcami Large Molecule Drugs CDMO Introduction
11.12.4 Alcami Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.12.5 Alcami Recent Development
11.13 Cytiva
11.13.1 Cytiva Company Detail
11.13.2 Cytiva Business Overview
11.13.3 Cytiva Large Molecule Drugs CDMO Introduction
11.13.4 Cytiva Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.13.5 Cytiva Recent Development
11.14 Thermo Fisher Scientific
11.14.1 Thermo Fisher Scientific Company Detail
11.14.2 Thermo Fisher Scientific Business Overview
11.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Introduction
11.14.4 Thermo Fisher Scientific Revenue in Large Molecule Drugs CDMO Business (2019-2024)
11.14.5 Thermo Fisher Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
